A federal advisory committee voted 9 to 6 on Tuesday that a first-of-its-kind diabetes drug should not be approved for use because of safety concerns, including a possible increased risk of breast and bladder cancers.

The advisory committee to the Food and Drug Administration said that while the drug, dapagliflozin, had some attractive features as a treatment for type 2 diabetes, there were too